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Abstract
Background: The association between anxiety and depression, and eczema is well known in the literature, but factors 
underlying this association remain unclear. Low levels of omega-3 fatty acids and female gender have been found to 
be associated with both depression and eczema. Somatization and health anxiety are known to be associated with 
anxiety and depression, further, somatization symptoms and health anxiety have also been found in several 
dermatological conditions. Accordingly, omega-3 fatty acid supplement, female gender, somatization and health 
anxiety are possible contributing factors in the association between anxiety and depression, and eczema. The aim of 
the study is to examine the relevance of proposed contributing factors for the association between anxiety and 
depression, and eczema, including, omega-3 fatty acid supplement, female gender, health anxiety and somatization.
Methods: Anxiety and depression was measured in the general population (n = 15715) employing the Hospital 
Anxiety and Depression Scale (HADS). Information on eczema, female gender, omega-3 fatty acid supplement, health 
anxiety and somatization was obtained by self-report.
Results: Somatization and health anxiety accounted for more than half of the association between anxiety/depression, 
and eczema, while the other factors examined were of minor relevance for the association of interest.
Conclusions: We found no support for female gender and omega-3 fatty acid supplement as contributing factors in 
the association between anxiety/depression, and eczema. Somatization and health anxiety accounted for about half of 
the association between anxiety/depression, and eczema, somatization contributed most. The association between 
anxiety/depression, and eczema was insignificant after adjustment for somatization and health anxiety. Biological 
mechanisms underlying the mediating effect of somatization are yet to be revealed.
Background
The field of psychodermatology addresses the interaction
between skin and mind, and the association between anx-
iety and depression, and eczema is well documented in
the literature [1-8]. However, despite of numerous
hypotheses, there is still surprisingly little empirical evi-
dence for mechanisms involved in this association.
Omega-3 fatty acid level has been suggested to be a
possible contributing factor in the association between
depression and atopic eczema [7]. This hypothesis is
inspired by reports of low levels of omega-3 fatty acids in
blood and development of atopic disease [9], and reports
of low dietary intake of omega-3 fatty acids and depres-
sion [10-12].
Timonen and colleagues have suggested that the associ-
ation between atopic disorders and depression is limited
to females only. This is based on their findings in two
large, population-based studies, where women suffering
from atopic diseases, compared with nonatopic subjects,
w e r e  f o u n d  t o  p o s s e s s  a n  e l e v a t e d  r i s k  f o r  d e v e l o p i n g
depression [7,13]. A corresponding association was not
found among males. Timonen and colleagues also pro-
pose that parity and female hormones may contribute in
the association between depression and atopic disorders
such as eczema [7,13]. This is based on reports of associa-
tions between parity and gestational age, and atopic dis-
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orders [14], and associations between multiparity, atopy,
and depression [15].
A substantial part of the psychodermatological litera-
ture has focused on atopic forms of eczema, and many of
the above referred hypotheses concerning possible
explanatory factors for the association between anxiety
and depression, and eczema presuppose the involvement
of atopy (elevated levels of IgE, in addition to "atopic
symptoms" [16]) as a part of the aetiological chain under-
lying this association. On this basis, we considered IgE
levels as a possible explanatory factor in the association
between anxiety, depression, and eczema, but we recently
published that there is no association between IgE levels,
and anxiety and depression [17]. On the basis of this nil
finding, IgE levels cannot be a mediating or confounding
factor in the association of interest. Therefore, we
decided not to include analyses of IgE in this manuscript.
According to Koo and Lebwohl, disfiguring skin condi-
tions can lead to psychological problems such as
decreased self-esteem, that may lead to depression or
symptoms of social phobia [1]. Several reports have
emphasized psychological mechanisms beyond anxiety
and depression, that may contribute in eczema: Eczema
may be worsened by emotional stress [1], and some
reports claim that eczema patients are more prone to
express psychosomatic symptoms than normal controls
[18]. According to a recent review by Gupta, a wide range
of somatization-related symptoms are found in dermato-
logical patients [19]. A according to the World Health
Organisation (WHO)'s International Classification of
Diseases, 10th revision (ICD-10), somatization is a men-
tal disorder characterized by experience of somatic symp-
toms without known organic etiology, where symptoms
often spread across organ systems, and vary over time
[20]. Whereas, somatization disorder is rare in the gen-
eral population, sub-clinical tendency of somatization is
common. There are also reports of higher prevalence of
hypochondria symptoms in eczema patients than in nor-
mal controls [21]. Hypochondria is an old clinical con-
cept referring to exaggerated health anxiety (health-
related worry and fear) and inadequate beliefs of suffering
from a serious medical disease [22]. It is well known that
anxiety and depression often are associated with both
somatization and health anxiety [23-25], but, according
to ICD-10, comorbidity with anxiety and/or depression is
not a criterion for the diagnosis of somatization disorder.
Due to the reported associations between eczema, and
anxiety, depression, somatization and health anxiety, it is
possible to suggest that somatization and health anxiety
could be contributing factors in the association between
anxiety and depression, and eczema, but as far as we
know, this has not been previously investigated.
Most studies within the field of psychodermatology are
based on clinical samples, commonly recruited from der-
matological clinics. Such studies are often criticized for
low statistical power and multiple selection biases. On
the other hand, the advantage of clinical studies is the
presumed good reliability of diagnoses of eczema, anxi-
ety, and depression. Compared to clinical studies, epide-
miological population-based studies are less vulnerable to
selection bias and are commonly more generously pow-
ered. There are few epidemiological population-based
studies within the psychodermatological field; among the
exceptions are Timonen and colleagues [7,8,13,26].
Despite the broad range of hypotheses concerning the
association between anxiety and depression, and eczema,
empirical support is scarce for most of them. The aim of
the present study is therefore to examine the relevance of
proposed contributing factors for the association
between anxiety and depression, and eczema, including
omega-3 fatty acid supplement, female gender, health
anxiety, and somatization.
Methods
Participants and data collection
The Hordaland Health Study (HUSK) was conducted as
collaboration between the National Health Screening
Service, the University of Bergen and local health services
of Hordaland County in Norway. All individuals born
1953-57, who resided in Hordaland County on December
31, 1997, were invited to the HUSK study. The target pop-
ulation counted 29400 individuals [27]. A total of 18581
(8598 men and 9983 women) both answered the first
questionnaire and came to clinical examination. A ran-
dom sample of about 6300 individuals born 1950-1951,
that participated in a previous (1992-93) health study in
Hordaland, were also invited. Finally, 18581 individuals
born 1953-57 (participation rate of 63%), and 4849 indi-
viduals born 1950-51 (participation rate of 77%) attended.
In the present study, we included only those who came to
clinical examination, and returned the second self-report
form, further excluding those without valid responses on
eczema and HADS variables (about 33% of the partici-
pants). Thus the final population consisted of 15 715 indi-
viduals.
Data collection in HUSK was performed over two
steps: First, participants were mailed a questionnaire and
an invitation to a health examination (measuring blood
pressure, height, weight and hip-waist ratio), where also
blood samples were taken. After handing in the first form
at the examination, the participants were given one of
two versions of a second form to be returned by post in a
prepaid envelope [27].
Measures
Anxiety and depression
The Hospital Anxiety and Depression Scale (HADS) is a
self-report questionnaire comprising 14 four-point scaledKlokk et al. BMC Dermatology 2010, 10:3
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items, seven for anxiety (HADS-A) and seven for depres-
sion (HADS-D) [28]. To avoid false positive cases in con-
text of somatic diseases, no somatic items or items
regarding sleeping difficulties are included. In accordance
with the findings on anxiety disorders and depression in
the National Comorbidity Survey [29], the HADS compo-
nents of anxiety and depression shares 30% variance [30].
According to a recent literature review covering 31 stud-
ies, HADS has shown good case-finding properties for
anxiety and depression in patient populations in primary
care and hospital settings [31]. A cut-off score of 8 on
both subscales was found to give an optimal balance
between sensitivity and specificity, both at about 0.80, for
depression and anxiety according to DSM-III and IV,
ICD-8 and 9. This is similar to the sensitivity and speci-
ficity of the General Health Questionnaire. According to
previous use of the HADS scale, anxiety and depression
were operationalized in two ways: By employing cut-offs
(cut-off score of 8 on both subscales), four groups were
identified as current anxiety only, current depression
only, current comorbid anxiety and depression, and a ref-
erence group (no disorder) [32,33]. Further, anxiety and
depression symptom load was measured continuously
employing HADS anxiety and depression sum-scores
[17].
Eczema
The eczema diagnosis in HUSK was based on self-report
questions extracted from three epidemiological studies
concerning hand eczema [34-36]. The use of self-report
for eczema has been validated against dermatologists'
diagnosis [37,38]. The self report question "have you had
hand eczema on any occasion during the past 12
months?" was validated in different occupational groups
[38] and resulted in 10-12.5% false negative cases com-
pared to diagnoses established by dermatologist. This
corresponds to a sensitivity of 53-59% and specificity of
96-99%.
HUSK contained dichotomous questions about eczema
similar to the self-report question used in the above
referred validation study: "Have you had eczema (red,
itching, sensitive, or fissured skin) on any occasion during
the last year?" Responses were recorded with reference to
hands, face, and body. The eczema variables were opera-
tionalized as any eczema, number of areas affected, and
hand, body and face eczema separately. A broader use of
the eczema concept has been suggested in the revised
nomenclature for allergy for global use. According to this
nomenclature, the term eczema is considered to be a gen-
eral term comprising both atopic and non-atopic ecze-
mas, further sub-classification of eczema will require
determination of underlying immunological mechanism
[16]. However, in the current study eczema questions are
general and further sub-classification beyond report of
body area involved is restricted.
Socio-demographic variables and health related behaviour
Socio-economic factors and health-related behaviours
are shown to be associated with both skin disease [39]
and anxiety and depression [40,41], thus socio-economic
factors might confound the association of interest. In
addition, female gender has been suggested by Timonen
and colleagues to moderate the association between
eczema and depression [7,13]. Consequently, we adjusted
for gender (data from public registries), marital status
(living with a partner or not), current smoking (dichot-
omy), household income (three levels), education (three
levels), and main occupation and industry, classified
according to Standard Classification of Occupations
(ISCO88), and Standard Industrial Classification (SIC94)
[27]. Different kinds of "wet work" (for instance work in
health care sector, hair dressers or cooks) are also among
the occupations included in this classification.
Physical health in HUSK
Somatic diagnoses of stroke, myocardial infarction,
angina pectoris, multiple sclerosis, asthma, diabetes mel-
litus, hay-fever, bronchitis, osteoporosis, and fibromyal-
g i a  w e r e  r e g i s t e r e d  a s  d i c h o t o m i e s .  I n  a d d i t i o n ,  a l l
current pharmacological treatments were registered in
open questions, also with responses for which somatic
diagnoses treatments were used for [42]. Common
responses like dietary supplements and alternative phar-
macological treatments were not included. From this list
131 common, non-acute conditions were identified,
including haematological, cardiovascular, gastrointesti-
nal, urogenital, hormonal, neurological, respiratory, neo-
plastic, immunologic, and infectious diseases. All
responses were encoded according to the Anatomical
Therapeutic Chemical Classification System (ATC) [43],
and the International Classification of Primary Care
(ICPC) [44], by a scientific committee. An index was
computed as the number of somatic diagnoses based on
the above information (9 self-reported somatic diagnoses
in addition to 131 somatic conditions that involve phar-
macological treatment). As the diagnosis of fibromyalgia
is symptom-based, thus touching on to the construct of
somatization, we included it as a separate dichotomy (as
opposed to be included in the indexes).
Somatization and health anxiety (Whiteley Index), measured 
in sub-sample I (n = 7024)
In HUSK, participants were asked to indicate any pres-
ence of 13 somatic symptoms from the ICD-10 symptom
criteria for F45.0 somatization disorder, and rate them as
to frequency scaled from 0 (almost never) to 4 (all the
time). One of these involved skin symptoms and was
omitted in this context to avoid circularity. To conserve
variance in the data, a mean score of responses across the
remaining 12 items was computed for every individual,
and the mean score represents "somatization" in the indi-
vidual. This somatization symptom score will, however,Klokk et al. BMC Dermatology 2010, 10:3
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be sensitive to organic aetiology. To make the index more
specific to symptoms relating to somatization, we adjust
all analyses for somatic diagnoses and medication for
somatic conditions (described above) before including
somatization in the models. Our Index for somatization
should not be compared to validated instruments for the
diagnosis of somatization disorder. Our index for somati-
zation was used as a dimensional measure (using a mean-
score of the 12 items) for tendency of somatization. How-
ever, this dimensional measure for somatization has also
been used in previous publications [33,45].
The Whiteley Index [46] is a self-report scale on hypo-
chondria and health anxiety consisting of 14 items, and
has sensitivity and specificity rates of 71% and 80% for the
DSM-IV definition of hypochondria [22,45]. The White-
ley Index has been found to be a valid screening instru-
ment in the assessment of hypochondria disorder [22],
but in this study it was used dimensionally to allow maxi-
mum variance and we describe it under the term "health
anxiety"[45]. In HUSK, the Whiteley Index was distrib-
uted to a sub-sample only; hence adjustments for health
anxiety were performed in a sub-sample including 7024
individuals (sub-sample I).
Omega-3 fatty acid supplement
Cod liver oil (containing on average 1.2 gram omega-3
fatty-acids per 5 ml) supplement was measured by self-
report of numbers of months with daily cod liver oil
intake, during the last year.
Hormonal replacement therapy, hormonal contraceptives, 
and parity
For women, we included self-report of parity (0 - 5 or
more children), current use of hormonal replacement
therapy (HRT) (Oestrogen tablets or plaster), and current
use of hormonal contraceptives (P-pill, or Mini-pill or
Hormone-spiral).
Statistical analysis
Sample characteristics were examined by descriptive sta-
tistics. Chi-square statistics were applied when exploring
differences in sample characteristics between men and
women. Pearson's correlation coefficients were calculated
to examine correlations between health anxiety, and som-
atization, and between anxiety/depression, and health
anxiety and somatization.
To test hypotheses of associations between anxiety and
depression, and eczema, logistic regression analyses were
applied. Anxiety, depression, and co-morbid anxiety/
depression were included as dependent variables, and
eczema as independent variable. Linear regression was
u s e d  t o  c o m p a r e  t h e  s t r e n g t h  o f  a s s o c i a t i o n s  b e t w e e n
eczema and somatization, eczema and health anxiety, and
eczema and anxiety/depression. Effects were given as
Odds Ratios (OR) for logistic regressions, and unstan-
dardized regression coefficients (B) for linear regressions.
All results were reported with 95% confidence intervals.
The proposed confounders and possible explanatory fac-
tors of the association between anxiety/depression, and
eczema were included in the regression model as covari-
ates in both bi- and multivariate logistic regression analy-
ses. No automatic procedures for including/excluding
variables in the regression model were used.
Age was not regarded a relevant confounder.
Ethics
The study was approved by the Regional Committee for
Medical Research Ethics of Western Norway and the
Norwegian Data Inspectorate.
Results
Descriptive characteristics of the study sample are
reported in Table 1. Any eczema was reported among
36% of the sample, distributed on hand eczema (20.2%),
body eczema (19.8%), and face eczema (9.2%). Both hand
eczema (24.2% in women vs. 15.4% in men) and face
eczema (9.9% vs.8.3%) were more prevalent in women
than in men (p < 0.01). The prevalence of body eczema
was nearly equal in men and women (about 20%).
According to the HADS definitions, 12.9% had current
anxiety only, 4.2% current depression only, and 7.5% co-
morbid anxiety/depression.
Associations between anxiety and depression, and eczema
Anxiety, depression, and co-morbid anxiety/depression
were associated with eczema across all body areas, the
exception being face eczema which was not associated
with depression in the absence of anxiety. Co-morbid
anxiety/depression had a stronger association to eczema
than current anxiety and depression only. The strongest
association was found between face eczema and co-mor-
bid anxiety/depression (Table 2, upper part).
One eczema by gender interaction was found to be sta-
tistically significant in association with anxiety/depres-
sion (Table 2, bottom part), this result is probably due to
statistical chance across 12 interaction analyses, because
with a p-value that was 0.03 for this analysis, only by set-
ting the level of significance at p = 0.025, this interaction
will turn out insignificant. Accordingly, this gender inter-
action would not be robust for a Bonferroni correction.
Analyses were also carried out for "pure" forms of hand,
face and body eczema (that is, not co-occurring with
eczema in other body areas) and anxiety/depression, giv-
ing principally the same results as in the initial analyses,
but generally with weaker associations (results not shown
in table). A dose-response relationship between number
of areas with eczema and anxiety/depression was found
(results not shown in table).Klokk  et al. BMC Dermatology 2010, 10:3
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Somatization, health anxiety, fibromyalgia and somatic 
diagnoses
Adjustment for the somatization and health anxiety
together represented about half the association between
anxiety and depression, and eczema (Table 3, sub-sample
I), somatization being a stronger factor here than health
anxiety. Pearson correlation between somatization and
health anxiety was considerable (r = 0.49, p < 0.01), thus
their explanatory effect for the association is partly over-
lapping.
Linear regression analyses, employing z-scored vari-
ables, showed that somatization and health anxiety were
m o r e  s t r o n g l y  a s s o c i a t e d  t o  e c z e m a  t h a n  a n x i e t y  a n d
depression, (unstandardized regression coefficient (B) =
0.37 (p < 0.01) for the association between somatization
and eczema, B = 0.22 (p < 0.01) for health anxiety/
eczema, B = 0.20 (p < 0.01) for anxiety/eczema, and B =
0.15 (p < 0.01) for depression and eczema).
Adjustment for Fibromyalgia alone contributed to
some extent and other somatic diagnoses (self-reported
somatic diagnoses and medication for somatic condi-
tions) explained a minor part of the association.
Other covariates
Adjustments for gender, socio-economic factors, occupa-
tion and industry ("wet work" is included here), omega-3
supplement and current smoking did not reduce OR sub-
stantially (Table 3). Adjustments for hormonal contracep-
Table 1: Descriptive characteristics.
Variables N at risk Percent
Age
Mean 43.0
SD 1.41
Range 41-48
Gender (males) 7115 45.3
Married/living with a partner (yes) 11718 74.6
Current smoking (yes) 5424 34.5
Household Income
0-17800 EUR 857 5.5
17815-47490 EUR 7122 45.3
47500 EUR or more 7086 45.1
Education
Compulsory only 2871 18.3
Secondary, non-university 7193 45.8
University 5651 36.0
Physical health*
No diagnosis 11203 71.3
1 diagnosis 3253 20.7
2 diagnoses 889 5.7
3 or more 370 2.4
Fibromyalgia (yes) 1053 6.7
Parity1
0 children 699 8.1
1 or more children [combined in this table only] 7732 89.9
Hormonal contraceptives2 (yes) 1672 19.4
HRT1 (yes) 414 4.8
SD, standard deviation; HRT, Hormonal replacement therapy (Oestrogen tablets or plaster);
EUR, Euro.
*Self-reported somatic diagnoses and medication for somatic conditions
1Women only (N = 8600).Klokk et al. BMC Dermatology 2010, 10:3
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tives and replacement therapy and parity did not account
for the association of interest (Table 3, lower part).
The association of interest (including candidate con-
founding/mediating factors) was also analyzed applying
HADS as a continuous variable, and with linear regres-
sion models. All conclusions were confirmed applying
this approach.
Discussion
The present study confirmed previous findings of an
association between anxiety and depression, and eczema
[2-8,47-49]. But more important, the study adds to the
current knowledge on the understanding of possible con-
tributing factors in this association. Somatization and
health anxiety accounted for about half of the association
between anxiety/depression, and eczema, and the associ-
ations of interest were insignificant after this adjustment.
Female gender and omega-3 fatty acid supplements have
in psychodermatological literature been proposed as con-
tributing factors relevant for the association of between
anxiety, depression, and eczema, but we were unable to
provide empirical support for these hypotheses.
The present study has several strengths, one of them
being the epidemiological population-based design
avoiding selection biases commonly found in clinical con-
texts.
Among the most important limitations to our study is
the self-report of eczema, which precludes sub-classifica-
tion beyond report of body area involved. Theoretically,
several forms of eczema could be included in the eczema
group due to the general form of the eczema questions
used in our study. It is not uncommon, however, to
employ a wider definition of eczema in large epidemio-
logical studies. In a study by Hanifin and Reed, [50] the
term "empirical eczema" was defined by several skin
symptoms that resemble the skin symptoms listed in the
HUSK questionnaire used in our study. Further, the valid-
ity of several self-reported skin complaints against clini-
cal signs was explored in a Norwegian, population-based,
validation study [51], finding that self-reported skin com-
plaints can be a valid tool for quantifying and exploring
skin diseases at population level. The use of self-reported
eczema represents a risk of misclassification (both false
positive and false negative cases compared to the result of
Table 2: Associations between anxiety and depression, and eczema.
Anxiety Depression Both
OR 95%CI OR 95%CI OR 95%CI
Men and women
Any eczema 1.49* 1.35-1.64 1.25* 1.04-1.49 1.55* 1.36-1.76
Hand eczema 1.41* 1.26-1.59 1.26* 1.02-1.54 1.32* 1.13-1.53
Face eczema 1.54* 1.32-1.79 1.27 0.96-1.69 1.67* 1.37-2.03
Body eczema 1.47* 1.31-1.65 1.43* 1.17-1.75 1.59* 1.37-1.84
Women
Any eczema 1.40* 1.23-1.58 1.16 0.88-1.53 1.66* 1.39-1.98
Hand eczema 1.28* 1.11-1.47 1.07 0.78-1.47 1.25* 1.02-1.52
Face eczema 1.41* 1.16-1.71 0.97 0.60-1.60 1.66* 1.29-2.14
Body eczema 1.49* 1.29-1.73 1.44* 1.05-1.98 1.59* 1.30-1.94
Men
Any eczema 1.54* 1.30-1.81 1.42* 1.13-1.78 1.42* 1.16-1.73
Hand eczema 1.49* 1.22-1.84 1.69* 1.29-2.21 1.44* 1.12-1.84
Face eczema 1.71* 1.33-2.21 1.59* 1.12-2.28 1.67* 1.23-2.26
Body eczema 1.44* 1.19-1.74 1.43* 1.10-1.85 1.59* 1.28-1.98
Interaction terms
Any eczema by gender 0.91 0.74-1.12 0.82 0.57-1.18 1.17 0.90-1.52
Hand eczema by gender 0.86 0.67-1.10 0.63* 0.42-0.96 0.87 0.63-1.19
Face eczema by gender 0.82 0.60-1.13 0.61 0.34-1.11 1.00 0.67-1.48
Body eczema by gender 1.04 0.82-1.32 1.01 0.67-1.52 1.00 0.74-1.35
OR, odds ratio; CI, confidence interval. *p < 0.05.Klokk et al. BMC Dermatology 2010, 10:3
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Table 3: Anxiety and depression as a function of eczema, with cumulative adjustments for possible contributing factors.
Anxiety Depression Both
Cumulative adjustments OR 95%CI OR 95%CI OR 95%CI
Total sample (N = 15715)
None 1.49* 1.35-1.64 1.25* 1.04-1.49 1.55* 1.36-1.76
Gender 1.45* 1.31-1.60 1.31* 1.09-1.56 1.55* 1.36-1.77
SES1 1.43* 1.30-1.59 1.28* 1.07-1.53 1.52* 1.33-1.73
Occupation/Industry 1.43* 1.30-1.59 1.26* 1.05-1.51 1.50* 1.31-1.71
Omega-3 supplement 1.42* 1.29-1.58 1.26* 1.06-1.51 1.50* 1.31-1.71
Current smoking 1.43* 1.26-1.51 1.26* 1.05-1.51 1.50* 1.31-1.72
Subsample I (N = 7024)
None 1.45* 1.24-1.69 1.41* 1.10-1.81 1.60* 1.32-1.95
Gender and SES1 1.40* 1.19-1.63 1.43* 1.11-1.84 1.56* 1.27-1.90
Fibromyalgia 1.37* 1.17-1.60 1.40* 1.08-1.80 1.51* 1.24-1.85
Other somatic diagnoses2 1.34* 1.15-1.57 1.40* 1.08-1.80 1.47* 1.20-1.80
Somatization3 1.15 0.98-1.35 1.27 0.98-1.64 1.21 0.97-1.50
Health anxiety 1.10 0.93-1.31 1.23 0.95-1.60 1.17 0.93-1.47
Adjusted for all factors above4 1.09 0.92-1.29 1.22 0.94-1.59 1.19 0.94-1.51
Female sub-sample (N = 8600)
None 1.40* 1.23-1.58 1.16 0.88-1.53 1.66* 1.39-1.98
SES1 1.39* 1.22-1.57 1.14 0.86-1.51 1.64* 1.38-1.96
Hormonal contraceptives 1.39* 1.22-1.57 1.14 0.86-1.50 1.64* 1.38-1.96
HRT5 1.38* 1.22-1.57 1.14 0.86-1.50 1.63* 1.37-1.95
Parity 1.38* 1.22-1.56 1.14 0.86-1.50 1.62* 1.36-1.94
OR, odds ratio; CI, confidence interval;
*p < 0.05.
1Educational level, marital status and income;
2Self-reported somatic diagnoses and medication for somatic conditions;
3 Somatic symptoms included in symptom criteria of the ICD-10 diagnosis F45.0 Somatization disorder (skin symptoms excluded);
4Including occupation/industry, omega-3 supplement and current smoking;
5Hormonal replacement therapy (Oestrogen tablets or Plaster).
a clinical examination), resulting in an underestimation of
the true strength of the association. Meding and col-
leagues reported good agreement between patients' self-
report of hand eczema and dermatologists' judgements
[37,38]. Validation of the question "have you had hand
eczema on any occasion during the last 12 months" indi-
cated false negative answers among 10-12.5% of the par-
ticipants [38]. This population survey is comparable to
our present study, indicating similar extent of misclassifi-
cation.
Another objection to our study, could be that hand
eczema is a singular clinical entity, and that the reliability
and validity of self-reported hand eczema cannot be gen-
eralized to eczema in other areas of the body. However,
we have no reason to assume the validity to be poorer for
other forms of self-reported eczema. In our analyses we
compared face, hand and body eczema and their associa-
tion to mental health, finding that the association was not
restricted to special sub-types of eczema. Future studies
of the validity of self-reported face and body eczema
might be warranted, but while awaiting these, we have to
assume that the validity of self-reported hand eczema can
be generalized to other body areas.
The use of HADS for assessment of anxiety and depres-
sion also implies self-report rather than clinical examina-
tion. Misclassification cannot be excluded, but is likely to
have been random; again resulting in an underestimation
of the true association.
Another important limitation to our study is the use of
a cross-sectional design, precluding inferences regarding
causality for the association between anxiety and depres-
sion, and eczema. Employing a cross-sectional design, itKlokk et al. BMC Dermatology 2010, 10:3
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is not possible to determine whether psychological symp-
toms can result from eczema, or if such symptoms are
part of the causative chain for skin disease.
How can we interpret the finding that somatization and
health anxiety explain most of the association between
anxiety and depression, and eczema? One possibility is
that health anxiety might represent selective attention to
common somatic symptoms [52-54], which again might
increase self-report of eczema. An alternative explanation
could be that anxiety, depression, health anxiety and
somatization are all a consequence of the burden of suf-
fering from chronic eczematous conditions. Another
explanation involves the possibility of a common factor in
anxiety, depression, health anxiety and somatization
which are correlated to eczema. In this perspective, our
finding that somatization and health anxiety account for
much of the association between anxiety/depression, and
eczema might be regarded an artefact resulting from
over-adjustments. However, the finding that somatization
is more strongly associated to eczema than anxiety/
depression makes us speculate that the association
between anxiety/depression, and eczema is actually
driven by somatization. Further, the large confounding
effect of the somatization variable might indicate that it
actually (at least partly) represents somatization, as pri-
mary adjustment for somatic diagnoses hardly attenuated
the association. This does obviously not equivalence to
clinical examinations. Adjustment for somatic diagnoses
prior to symptoms of somatization, in the association of
interest, was our attempt to exclude organic aetiology in
somatization. Using an index based on questions derived
from the somatization diagnostic criteria doesn't have the
same validity as employing a validated instrument, but to
the best of our knowledge, there is yet no well-validated
and widely used instrument for somatization. Acknowl-
edging the limitations of our measure; adjustment for
somatization (on top of somatic diagnoses) explained
about forty percent of the association of interest.
According to Koblenzer [55] the common origin of the
skin and the central nervous system (CNS) from the
embryonic neuro-ectoderm could explain the ongoing
two-way physiologic communication between emotional
input, CNS functioning, and cutaneous expression. Con-
tinuing Koblenzer's line of thought, it might be specu-
lated that some forms of eczema and somatization may
be mediated through a common immunological factor. A
possible common immunological factor in eczema and
somatization could be cytokines, which are known to be
involved in the immunological mechanisms underlying
eczema [56] and suggested by Dantzer [57] to underlie
somatization. Dantzer suggests that stress (psychological
included) can induce sensitization of the cytokine system
in the brain, which further may lead to symptoms of
mood disorders (anxiety and depression), and expression
of somatic symptoms that resemble those seen in somati-
zation [57]. According to ICD-10 [20], some skin symp-
toms (skin spots and discoloration of the skin) are already
included in the symptom list for F45, somatization disor-
der. So, another possibility could be that somatization
may lead to psychological stress reactions in the body,
and psychological stress has been found to worsen or
trigger outbursts of eczema [1].
Omega-3 fatty acid intake is also hypothesized to
account for the association of interest [7,12,13], but our
results provide no support for this hypothesis. It might be
objected that omega-3 fatty acid intake was measured by
self-report of dietary supplements (cod liver oil) only, and
in fairly moderate doses, further omega-3 fatty acid con-
tent in regular diet was not accounted for. There are obvi-
ous limitations to our omega-3 fatty acid measure,
possibly reducing expected effect sizes. However, if
omega-3 fatty acid intake was a major factor in explaining
the association, we would expect at least some attenua-
tion of the association of interest. Further, we cannot
exclude the possibility that a higher daily intake of
omega-3 fatty acids than reported in this study is needed
to demonstrate a mediating effect.
A gender-specific association between eczema and
depression has been suggested by Timonen et al.
[7,13,26]. Stratified analyses by gender, and testing of the
interaction-term eczema by gender did not support this
hypothesis, even if one significant gender-interaction was
found across 12 analyses, but in this analysis the associa-
tion between hand eczema and depression was stronger
in men than in women, the opposite of Timonens hypoth-
esis.
In the light of an epidemiological population-based
study we have been able to examine several of the sug-
gested contributing factors in the association between
anxiety/depression, and eczema. The lack of support for
different candidate explanations for the association of
interest might be somewhat surprising. We note that
somatization and health anxiety accounted for most of
the association. The literature on somatization in eczema
is scarce, and should be examined more thoroughly in
future studies. Beyond the candidate explanatory factors
discussed here, we are left with speculations as to biologi-
cal mechanisms involved. Future research into the aetiol-
ogy underlying the association between anxiety and
depression, and eczema might benefit from including the
concept of somatization and health anxiety.
Conclusions
The current study confirmed previous findings of an
association between anxiety and depression, and eczema,
but somatization and health anxiety accounted for more
than half of the association of interest, and the associa-
tion was insignificant after this adjustment.Klokk et al. BMC Dermatology 2010, 10:3
http://www.biomedcentral.com/1471-5945/10/3
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We found no support for previously suggested contrib-
uting factors in the association between anxiety/depres-
sion, and eczema such as omega-3 fatty acid supplement
and female gender.
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